在特殊情况下治疗结核病

M. Kafle
{"title":"在特殊情况下治疗结核病","authors":"M. Kafle","doi":"10.3329/bjm.v35i20.73388","DOIUrl":null,"url":null,"abstract":"Treatment of Mycobacterium tuberculosis infection (tuberculosis disease) involves the use of multiple antimicrobials over several months. Therapy directed against tuberculosis (anti-tubercular therapy, or ATT) consists of rifampicin and isoniazid given daily for 6 months and pyrazinamide and ethambutol given daily for 2 months. This therapy might need customization in some special situations. Chronic kidney disease (CKD) is a special state where the individual possesses higher risk of developing tuberculosis disease as compared to non-CKD population. Patients on dialysis may be up to 10 times the risk. Furthermore, drug metabolism and excretion is also abnormal in this situation. Ethambutol and pyrazinamide are excreted by the kidneys. Therefore, if failed kidneys can’t adequately remove the drugs, accumulation to toxic levels might be the fate.\nIn glomerular filtration rate (GFR) of more than 30ml/min, normal antitubercular regimen may be utilized following the lower end of the recommended dosing per kg body weight with vigilant surveillance for adverse events. In conditions of advanced CKD, ethambutol needs dose adjustment according to the level of GFR as guided by serum creatinine level. However, to ensure optimal therapeutic levels of the drugs and avoid subtherapeutic levels, switching the schedule of therapy from daily to thrice weekly at full dosage has also been recommended. This should follow the directly observed strategy as followed in the treatment of tuberculosis. These strategies may work well for drug susceptible infections but in cases of drug resistant disease, susceptibility pattern should be followed. In hemodialysis patients, antitubercular drugs should be administered after hemodialysis. Patients with solid organ transplantation are at higher than normal risk for tuberculosis. This risk has been mentioned to be as high as 30 times. Furthermore, by the virtue of their use of immunosuppressive drugs, use of rifampicin in the antitubercular regimen is tricky. Rifampicin induces the metabolism of calcinurine inhibitors, demanding up titration of these immunosuppressive drugs by double or more the previous dose. Moreover, some authorities suggest replacing rifampicin by rifabutin. In conclusion, treatment of tuberculosis needs customization in special circumstances.\nBangladesh J Medicine 2024; Vol. 35, No. 2, Supplementation: 141-142","PeriodicalId":516125,"journal":{"name":"Bangladesh Journal of Medicine","volume":"27 31","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treating tuberculosis in special situations\",\"authors\":\"M. Kafle\",\"doi\":\"10.3329/bjm.v35i20.73388\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Treatment of Mycobacterium tuberculosis infection (tuberculosis disease) involves the use of multiple antimicrobials over several months. Therapy directed against tuberculosis (anti-tubercular therapy, or ATT) consists of rifampicin and isoniazid given daily for 6 months and pyrazinamide and ethambutol given daily for 2 months. This therapy might need customization in some special situations. Chronic kidney disease (CKD) is a special state where the individual possesses higher risk of developing tuberculosis disease as compared to non-CKD population. Patients on dialysis may be up to 10 times the risk. Furthermore, drug metabolism and excretion is also abnormal in this situation. Ethambutol and pyrazinamide are excreted by the kidneys. Therefore, if failed kidneys can’t adequately remove the drugs, accumulation to toxic levels might be the fate.\\nIn glomerular filtration rate (GFR) of more than 30ml/min, normal antitubercular regimen may be utilized following the lower end of the recommended dosing per kg body weight with vigilant surveillance for adverse events. In conditions of advanced CKD, ethambutol needs dose adjustment according to the level of GFR as guided by serum creatinine level. However, to ensure optimal therapeutic levels of the drugs and avoid subtherapeutic levels, switching the schedule of therapy from daily to thrice weekly at full dosage has also been recommended. This should follow the directly observed strategy as followed in the treatment of tuberculosis. These strategies may work well for drug susceptible infections but in cases of drug resistant disease, susceptibility pattern should be followed. In hemodialysis patients, antitubercular drugs should be administered after hemodialysis. Patients with solid organ transplantation are at higher than normal risk for tuberculosis. This risk has been mentioned to be as high as 30 times. Furthermore, by the virtue of their use of immunosuppressive drugs, use of rifampicin in the antitubercular regimen is tricky. Rifampicin induces the metabolism of calcinurine inhibitors, demanding up titration of these immunosuppressive drugs by double or more the previous dose. Moreover, some authorities suggest replacing rifampicin by rifabutin. In conclusion, treatment of tuberculosis needs customization in special circumstances.\\nBangladesh J Medicine 2024; Vol. 35, No. 2, Supplementation: 141-142\",\"PeriodicalId\":516125,\"journal\":{\"name\":\"Bangladesh Journal of Medicine\",\"volume\":\"27 31\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bangladesh Journal of Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3329/bjm.v35i20.73388\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bangladesh Journal of Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3329/bjm.v35i20.73388","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

结核分枝杆菌感染(结核病)的治疗需要在数月内使用多种抗菌药物。针对结核病的疗法(抗结核疗法,或 ATT)包括每天服用利福平和异烟肼,持续 6 个月,以及每天服用吡嗪酰胺和乙胺丁醇,持续 2 个月。在某些特殊情况下,这种疗法可能需要定制。慢性肾病是一种特殊疾病,与非慢性肾病患者相比,慢性肾病患者罹患结核病的风险更高。透析患者的风险可能高达 10 倍。此外,在这种情况下,药物代谢和排泄也会出现异常。乙胺丁醇和吡嗪酰胺由肾脏排泄。在肾小球滤过率(GFR)超过 30 毫升/分钟的情况下,可按照每公斤体重推荐剂量的下限使用正常的抗结核治疗方案,并警惕不良反应的发生。在晚期慢性肾功能衰竭的情况下,乙胺丁醇的剂量需要根据血清肌酐水平来调整。不过,为了确保药物达到最佳治疗水平,避免出现治疗水平以下的情况,也有人建议将每日全剂量治疗改为每周三次全剂量治疗。这应遵循治疗结核病时采用的直接观察策略。这些策略可能对药物易感性感染有效,但对于耐药性疾病,则应遵循药物易感性模式。对于血液透析患者,应在血液透析后服用抗结核药物。接受实体器官移植的患者罹患结核病的风险高于常人。据说这种风险高达 30 倍。此外,由于使用免疫抑制剂,在抗结核治疗中使用利福平也很棘手。利福平会诱导钙化抑制剂的新陈代谢,因此需要将这些免疫抑制剂的剂量增加一倍或更多。此外,一些权威人士建议用利福布汀替代利福平。总之,结核病的治疗需要在特殊情况下进行定制:141-142
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Treating tuberculosis in special situations
Treatment of Mycobacterium tuberculosis infection (tuberculosis disease) involves the use of multiple antimicrobials over several months. Therapy directed against tuberculosis (anti-tubercular therapy, or ATT) consists of rifampicin and isoniazid given daily for 6 months and pyrazinamide and ethambutol given daily for 2 months. This therapy might need customization in some special situations. Chronic kidney disease (CKD) is a special state where the individual possesses higher risk of developing tuberculosis disease as compared to non-CKD population. Patients on dialysis may be up to 10 times the risk. Furthermore, drug metabolism and excretion is also abnormal in this situation. Ethambutol and pyrazinamide are excreted by the kidneys. Therefore, if failed kidneys can’t adequately remove the drugs, accumulation to toxic levels might be the fate. In glomerular filtration rate (GFR) of more than 30ml/min, normal antitubercular regimen may be utilized following the lower end of the recommended dosing per kg body weight with vigilant surveillance for adverse events. In conditions of advanced CKD, ethambutol needs dose adjustment according to the level of GFR as guided by serum creatinine level. However, to ensure optimal therapeutic levels of the drugs and avoid subtherapeutic levels, switching the schedule of therapy from daily to thrice weekly at full dosage has also been recommended. This should follow the directly observed strategy as followed in the treatment of tuberculosis. These strategies may work well for drug susceptible infections but in cases of drug resistant disease, susceptibility pattern should be followed. In hemodialysis patients, antitubercular drugs should be administered after hemodialysis. Patients with solid organ transplantation are at higher than normal risk for tuberculosis. This risk has been mentioned to be as high as 30 times. Furthermore, by the virtue of their use of immunosuppressive drugs, use of rifampicin in the antitubercular regimen is tricky. Rifampicin induces the metabolism of calcinurine inhibitors, demanding up titration of these immunosuppressive drugs by double or more the previous dose. Moreover, some authorities suggest replacing rifampicin by rifabutin. In conclusion, treatment of tuberculosis needs customization in special circumstances. Bangladesh J Medicine 2024; Vol. 35, No. 2, Supplementation: 141-142
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信